Clinical trials (JO25567, NEJ026, and RELAY) also found that erlotinib plus vascular endothelial growth factor (VEGF) or VEGF receptor inhibitor significantly prolonged PFS among patients with EGFR‐mutant NSCLC.24, 25, 26. Here, VEGFA is linked to non-small cell lung carcinoma.